GNN monthly update: May' 22

568 Hits

NITAG publications and updates:

 

COVID-19 additional Booster doses:

  • CDC provided clinical considerations for a Second COVID-19 Vaccine Booster Dose, summarized in a one pager here.
  • NACI released initial guidance on a second booster dose of COVID-19 vaccines in Canada, urging jurisdictions to prepare for the rapid deployment of a second COVID-19 vaccine booster dose program over the coming weeks prioritizing the following populations, as close surveillance and assessment suggest concerning trends in the COVID-19 pandemic. More here.
  • CAVEI (Chile NITAG) recommends a third booster dose five to six months after the second booster, in people over 65 years of age, in immunosuppressed people, in people with chronic diseases and in health workers, according to the specifications defined for each group by the National Program for Immunizations from the Ministry of Health. Preferentially administer mRNA vaccines. In cases where there is contraindication of using mRNA vaccines, use inactivated vaccines. More here.
  • ATAGI has extended its recommendation on an additional winter booster to other people at increased risk, to be given 4 months after their first booster dose. This applies to people aged 16-64 who have a medical condition that increases the risk of severe COVID-19 illness (see Table 1 for expanded groups AND people with disability with significant or complex health needs or multiple comorbidities which increase risk of poor outcome from COVID-19. More here.
  • STIKO recommends a 2nd booster vaccination (at the earliest 3 months after the 1st booster) with an mRNA vaccine for 70-year-old, for residents in care facilities and for people with immunodeficiency after they have completed their primary series and received the 1st booster. The second booster vaccination is also recommended for those working in medical and nursing facilities, but no earlier than 6 months after the first booster vaccination. More here.
  • the French NITAG recommends administering a second booster dose 6 months after the first booster to people over the age of 65 who so wish and who are either at very high risk of a severe form of the disease, or polypathological.
  • The Finnish NITAG recommends a Fourth doses recommended to all >80 years of age and for those living in a care home for older adults , AND Older people needing care at home (no strict age limit )and slightly broadened the recommendation in May to other fragile older adults.

 

  • In Belgium, as of May 2022, the NITAG does not recommend a second booster dose for the general population and does not recommend a systematic second booster dose for people over 80 years of age and residents of nursing homes and care communities (regardless of their age). More here.

 

COVID-19 scenarios for the winter season:

  • Similarly to WHO SAGE, the French NITAG developed 3 scenarios of the epidemiological situation for the winter season and each scenario is associated with an appropriate vaccination strategy. As of May 2022 and bearing in mind the multiple uncertainties, the French NITAG considers scenario 2 characterized by the occurrence of periodic epidemic outbreaks as the most likely. Therefore, the French NITAG recommends the vaccination of people at risk of a severe disease (in particular, immunocompromised people and those around them, people aged 65 and over and/or people with comorbidities) and to consider the vaccination of healthcare professionals (in particular with regard to vaccine efficacy data against asymptomatic forms of the disease). For logistical reasons,the French NITAG  recommends combining the vaccination campaign with that of the influenza, and to consider that in the absence of an epidemic wave linked to Covid-19 by next fall, the start date of the Covid-19 campaign is determined by the start date of the seasonal flu vaccination.

 

COVID-19 children vaccination:

  • STIKO updated their recommendation for children (5-11 y) vaccination. Children with comorbidities should continue to receive a primary series vaccination with 2 doses and receive a booster. Healthy children who are in close contact with persons at high risk of severe COVID-19  should receive a primary series vaccination with 2 doses. For all other healthy children STIKO recommends, for the time being, a single dose . More info in German here.
  • ACIP updated their Evidence to Recommendation Framework on Pfizer-BioNTech COVID-19 booster in children aged 5-11 years, available here.

 

Monkeypox:

 

SAGE resources:

COVID-19:

  • WHO published an interim statement on the use of additional booster doses of Emergency Use Listed mRNA vaccines against COVID-19, available here. The data summarized in the interim statement was presented at the GNN webinar by Dr Shalini Desai along with a more generic presentation on booster vaccination by Dr Arnaud Didierlaurent, whose presentation is attached.
  • SAGE recommends the 11th COVID-19 vaccine: Cansino. The  Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 is available here, along with the annexes and background document.
  • WHO will publish an interim statement on hybrid immunity shortly. The interim statement will be available on the SAGE newsroom webpage.

 

Other topics:

 

WHO resources:

Several resources related to Increasing vaccination demand and uptake have been developed:

  • Behavioural and social drivers of vaccine uptake: tools and practical guidance – available in English here.
  • Human-centred design for tailoring immunization programmes: a practical guide that can be used for any priority group or vaccine across the life course and enhances the ability of programmes to listen and learn to better respond to community needs.
  • A Quality Immunization Services Planning Guide highlighting key actions at different levels of the health system to monitor, strengthen, and maintain the quality and convenience of services.

 

Partners resources:

  • ECDC developed a Risk assessment: Monkeypox multi-country outbreak, available here.

 

Webinars:

Through the Global Vaccine and Immunization Research Forum (GVIRF) collaboration, World Health Organization, NIAID, and the Bill & Melinda Gates Foundation are organizing a webinar :

Webinar Title: Vaccines as Tools to Prevent Antimicrobial Resistance: advances, challenges and future development

When: June 23 2022, 3-6 pm (CEST), 9-12 am (EDT), 6-9 am (PDT)

Registration (no-cost): https://who.zoom.us/webinar/register/WN_Iudu_2LtRIqv6hA6IkCkBQ   

Purpose: This webinar will explore the mechanisms, evidence and value of vaccines in preventing AMR. A panel of experts will discuss what are the challenges to ensure that vaccines to prevent AMR are developed and widely used.

  

pdf
File Name: GNNwebinar MAy 2nd 2022 Didierlaurent.pdf
File Size: 3 MB
Download File
0